Acrivon Other Assets vs Accounts Payable Analysis

ACRV Stock

7.35 0.19 2.65%

Acrivon Therapeutics, financial indicator trend analysis is way more than just evaluating Acrivon Therapeutics, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Acrivon Therapeutics, is a good investment. Please check the relationship between Acrivon Therapeutics, Other Assets and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acrivon Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Other Assets vs Accounts Payable

Other Assets vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Acrivon Therapeutics, Other Assets account and Accounts Payable. At this time, the significance of the direction appears to have pay attention.

The correlation between Acrivon Therapeutics,'s Other Assets and Accounts Payable is -0.99. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Acrivon Therapeutics, Common, assuming nothing else is changed. The correlation between historical values of Acrivon Therapeutics,'s Other Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of Acrivon Therapeutics, Common are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Other Assets i.e., Acrivon Therapeutics,'s Other Assets and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.99

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Other Assets

Accounts Payable

An accounting item on the balance sheet that represents Acrivon Therapeutics, obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Acrivon Therapeutics, are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Acrivon Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Acrivon Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acrivon Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Selling General Administrative is likely to climb to about 22.1 M in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	16.2M	32.7M	66.7M	70.0M
Cost Of Revenue	832K	1.1M	536K	680.9K

Total Operating Expenses Cost Of Revenue

Acrivon Therapeutics, fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		0.96	0.88	0.82	0.87	0.84	0.98	-0.68	-0.81	0.69	0.72	0.78	0.59	-0.62	0.99	0.72	0.22	0.94	0.89	0.39	0.87	0.97	-0.53	0.99	0.9	0.99
Short Long Term Debt Total	0.96		0.79	0.77	0.7	0.72	0.98	-0.86	-0.77	0.69	0.89	0.63	0.42	-0.6	0.98	0.65	0.47	0.81	0.75	0.63	0.7	0.97	-0.52	0.98	0.77	0.98
Other Current Liab	0.88	0.79		0.91	0.9	0.93	0.9	-0.42	-0.93	0.84	0.47	0.58	0.37	-0.81	0.89	0.74	-0.09	0.84	0.97	0.09	0.9	0.92	-0.64	0.89	0.97	0.88
Total Current Liabilities	0.82	0.77	0.91		0.77	0.95	0.86	-0.45	-1.0	0.98	0.53	0.41	0.17	-0.95	0.85	0.93	-0.08	0.73	0.85	0.16	0.77	0.87	-0.89	0.85	0.86	0.83
Total Stockholder Equity	0.87	0.7	0.9	0.77		0.92	0.8	-0.23	-0.78	0.63	0.29	0.84	0.71	-0.59	0.82	0.71	-0.27	0.96	0.98	-0.11	1.0	0.82	-0.48	0.82	0.98	0.81
Net Tangible Assets	0.84	0.72	0.93	0.95	0.92		0.83	-0.3	-0.95	0.87	0.37	0.62	0.42	-0.85	0.83	0.92	-0.26	0.87	0.94	-0.04	0.92	0.85	-0.79	0.83	0.95	0.82
Property Plant And Equipment Net	0.98	0.98	0.9	0.86	0.8	0.83		-0.74	-0.86	0.77	0.78	0.65	0.43	-0.71	1.0	0.72	0.29	0.86	0.87	0.47	0.8	1.0	-0.59	1.0	0.88	0.99
Net Debt	-0.68	-0.86	-0.42	-0.45	-0.23	-0.3	-0.74		0.44	-0.43	-0.99	-0.28	-0.1	0.34	-0.74	-0.32	-0.85	-0.41	-0.32	-0.94	-0.23	-0.72	0.29	-0.74	-0.34	-0.75
Retained Earnings	-0.81	-0.77	-0.93	-1.0	-0.78	-0.95	-0.86	0.44		-0.97	-0.51	-0.41	-0.17	0.95	-0.84	-0.91	0.09	-0.74	-0.87	-0.14	-0.78	-0.88	0.88	-0.85	-0.88	-0.83
Accounts Payable	0.69	0.69	0.84	0.98	0.63	0.87	0.77	-0.43	-0.97		0.5	0.2	-0.05	-0.99	0.75	0.9	-0.06	0.57	0.74	0.18	0.63	0.79	-0.94	0.75	0.75	0.73
Cash	0.72	0.89	0.47	0.53	0.29	0.37	0.78	-0.99	-0.51	0.5		0.31	0.12	-0.41	0.78	0.41	0.8	0.46	0.37	0.91	0.29	0.76	-0.38	0.78	0.4	0.79
Non Current Assets Total	0.78	0.63	0.58	0.41	0.84	0.62	0.65	-0.28	-0.41	0.2	0.31		0.96	-0.12	0.69	0.42	-0.04	0.92	0.74	0.03	0.84	0.64	-0.08	0.68	0.74	0.71
Non Currrent Assets Other	0.59	0.42	0.37	0.17	0.71	0.42	0.43	-0.1	-0.17	-0.05	0.12	0.96		0.12	0.48	0.22	-0.11	0.79	0.57	-0.09	0.71	0.42	0.15	0.47	0.57	0.5
Other Assets	-0.62	-0.6	-0.81	-0.95	-0.59	-0.85	-0.71	0.34	0.95	-0.99	-0.41	-0.12	0.12		-0.67	-0.87	0.14	-0.5	-0.71	-0.09	-0.59	-0.73	0.94	-0.68	-0.71	-0.65
Cash And Short Term Investments	0.99	0.98	0.89	0.85	0.82	0.83	1.0	-0.74	-0.84	0.75	0.78	0.69	0.48	-0.67		0.72	0.29	0.88	0.87	0.46	0.82	1.0	-0.57	1.0	0.88	1.0
Common Stock Shares Outstanding	0.72	0.65	0.74	0.93	0.71	0.92	0.72	-0.32	-0.91	0.9	0.41	0.42	0.22	-0.87	0.72		-0.19	0.7	0.74	0.06	0.71	0.73	-0.93	0.72	0.75	0.71
Non Current Liabilities Total	0.22	0.47	-0.09	-0.08	-0.27	-0.26	0.29	-0.85	0.09	-0.06	0.8	-0.04	-0.11	0.14	0.29	-0.19		-0.06	-0.2	0.97	-0.27	0.26	0.16	0.29	-0.17	0.3
Other Current Assets	0.94	0.81	0.84	0.73	0.96	0.87	0.86	-0.41	-0.74	0.57	0.46	0.92	0.79	-0.5	0.88	0.7	-0.06		0.93	0.09	0.96	0.86	-0.43	0.88	0.93	0.89
Other Stockholder Equity	0.89	0.75	0.97	0.85	0.98	0.94	0.87	-0.32	-0.87	0.74	0.37	0.74	0.57	-0.71	0.87	0.74	-0.2	0.93		-0.03	0.98	0.88	-0.56	0.87	1.0	0.86
Total Liab	0.39	0.63	0.09	0.16	-0.11	-0.04	0.47	-0.94	-0.14	0.18	0.91	0.03	-0.09	-0.09	0.46	0.06	0.97	0.09	-0.03		-0.11	0.43	-0.09	0.46	0.0	0.47
Net Invested Capital	0.87	0.7	0.9	0.77	1.0	0.92	0.8	-0.23	-0.78	0.63	0.29	0.84	0.71	-0.59	0.82	0.71	-0.27	0.96	0.98	-0.11		0.82	-0.48	0.82	0.98	0.81
Property Plant And Equipment Gross	0.97	0.97	0.92	0.87	0.82	0.85	1.0	-0.72	-0.88	0.79	0.76	0.64	0.42	-0.73	1.0	0.73	0.26	0.86	0.88	0.43	0.82		-0.6	1.0	0.9	0.99
Short Long Term Debt	-0.53	-0.52	-0.64	-0.89	-0.48	-0.79	-0.59	0.29	0.88	-0.94	-0.38	-0.08	0.15	0.94	-0.57	-0.93	0.16	-0.43	-0.56	-0.09	-0.48	-0.6		-0.57	-0.57	-0.55
Total Current Assets	0.99	0.98	0.89	0.85	0.82	0.83	1.0	-0.74	-0.85	0.75	0.78	0.68	0.47	-0.68	1.0	0.72	0.29	0.88	0.87	0.46	0.82	1.0	-0.57		0.88	1.0
Capital Stock	0.9	0.77	0.97	0.86	0.98	0.95	0.88	-0.34	-0.88	0.75	0.4	0.74	0.57	-0.71	0.88	0.75	-0.17	0.93	1.0	0.0	0.98	0.9	-0.57	0.88		0.87
Net Working Capital	0.99	0.98	0.88	0.83	0.81	0.82	0.99	-0.75	-0.83	0.73	0.79	0.71	0.5	-0.65	1.0	0.71	0.3	0.89	0.86	0.47	0.81	0.99	-0.55	1.0	0.87

Click cells to compare fundamentals

Acrivon Therapeutics, Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Acrivon Stock Analysis

When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Acrivon Other Assets vs Accounts Payable Analysis

Other Assets vs Accounts Payable

Other Assets vs Accounts Payable Correlation Analysis

Correlation Coefficient

Other Assets

Accounts Payable

Acrivon Therapeutics, fundamental ratios Correlations

Acrivon Therapeutics, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Acrivon Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 1.0	Cash And Short Term Investments

Retained Earnings	- 1.0	Total Current Liabilities
Other Assets	- 0.99	Accounts Payable
Cash	- 0.99	Net Debt
Accounts Payable	- 0.97	Retained Earnings
Retained Earnings	- 0.95	Net Tangible Assets
Other Assets	- 0.95	Total Current Liabilities